The immune system is a powerful agent against cancer. Small actions initiate large effects…

Yet cancer cells ‘escape’ the immune system and also actively suppress our immune defenses.

  • Susavion’s MVPM™ Technology platform is a promising new advancement in the field of immunotherapy
  • Carbohydrates are well known to stimulate the immune system and their receptor targets are well defined
    • Carbohydrates are poor drug candidates
  • Appropriately designed peptide sequences can mimic the activity of carbohydrates and access the cell surface
  • MVPM Technology enables Susavion to create peptides that bind to and activate key receptors with high specificity and avidity
  • Our proprietary peptides have been shown to successfully activate the immune system and generate anti-tumor responses


Design innovative peptide based immunotherapies that
bind lectin-type receptors to activate cellular processes.

Why this approach?

Peptide drugs can be designed to selectively activate the immune system to safely respond to the threat of the disease without triggering immunotoxicity.

Benefits of MVPM Technology

  • Susavion offers significant expertise in molecular biology and design of immunostimulatory peptides targeting a variety of receptors
  • Enables design of receptor-active peptides with four important attributes
    • High specificity
    • High avidity
    • Receptor cross-linking
    • Immunologic cross-talk
  • High development potential in oncology, HIV and other infectious diseases
  • Demonstrated preclinical POC with lead peptide (svL4) in murine model of difficult-to-treat glioblastoma

 Susavion pipeline

A series of peptides, svC2, sv6B, sv6C, svH1C and svH1D, are effective at nanomolar concentrations in eliminating HIV-1 in cultures of peripheral blood mononuclear cells in the presence of non-neutralizing antibodies from HIV-positive patients. Peptide svL4 significantly extended life when administered in conjunction with low doses of radiation in a model mouse system in which glioblastoma cells were implanted into brains.  sv6D and svL4 suppressed ascites formation extending survival in a mouse ovarian model. These synthetic peptide drugs have promise as biological response modifiers and should strongly enhance the immune defense in treatment of viral infections and cancer.